Editorials

Fibrin glue

Modern surgical techniques are efficient at securing haemostasis, but oozing of blood from multiple pinpoints on a large raw surface remains difficult to control. The use of electrocautery, sutures, or metal clips and staples may not be appropriate in delicate surgery on small yet functionally vital tissues and structures. In these settings fibrin glue is ideal for topical application to secure haemostasis. In cardiovascular and thoracic surgery, for example, fibrin glue may be sprayed with use of pressurised gas or compressed air to arrest bleeding from the surfaces of the heart, pericardium, mediastinum, and pleura.^4,5 It may be used in a similar way to form a thin film on the liver or the liver bed, or both,⁶ and in neurosurgical,⁷ ophthalmological,⁸ and some otolaryngological operations⁹; in vitro fertilisation¹⁰; and other microsurgery.¹¹ A further obvious indication for fibrin glue is external oozing of blood in patients with haemophilia.¹² Fibrin glue is not, however, a substitute for good surgical technique, and it is of little value in arresting arterial bleeds.

Fibrin glue has other uses besides haemostasis. It can seal leaks of air or fluid¹³ and secure anastomoses,¹⁴ and it is used in orthopaedic¹⁵ and plastic surgery.¹⁶ In all these indications the biologically interactive fibrin sealant is absorbed after it has done its job. Mixtures of fibrin glue and antibiotics are being used for local delivery of antimicrobial activity¹⁷; when applied to contaminated surgical wounds the combination may discourage the formation of adhesions.^18,19

Fibrin glue is a blood product obtained from either commercial sources or some regional blood transfusion centres. The commercial products are produced from pools of plasma, and the final products usually contain high yields of fibrinogen and, as a result, produce firm coagulums. Fibrin glue derived from individual volunteer donations may have a low concentration of fibrinogen, but newer methods for small scale production are claimed to produce fibrinogen yields and coagulum tensile strengths similar to those of the commercial products.^5,9 Until recently the thrombin used in preparations of fibrin glue was of bovine origin and caused a few serious systemic reactions including anaphylaxis and coagulopathy owing to the development of antibodies to thrombin.^5,20 The problem has been solved by the use of human thrombin.

Non-commercial fibrin glue can be prepared from either homologous or autologous plasma; the autologous source avoids any possible risk of viral transmission. Homologous fibrin glue is prepared from donations screened in the standard, rigorous way and is as safe as other tested blood products. Most viruses can be inactivated by solvent detergent treatment, but this is ineffective against some viruses such as parvovirus B19²¹ and hepatitis A virus.²² Fibrin glue prepared from virally inactivated plasma is being assessed for safety and efficacy.²³ Another approach is to prepare fibrin glue from homologous fresh frozen plasma from donors in whom current tests for viral markers at least six months after the donation yield negative results. This simple retrospective accreditation measure excludes the theoretical possibility of the donors having been in the "window period" when they gave blood or plasma.

Despite the established value of fibrin glue for a range of surgical indications its use is still restricted to a few surgical specialties and on a named patient basis. It is widely used in most European countries. Concern about safety and unawareness of potential applications are the main factors limiting the availability and use of fibrin glue in Britain and the United States.⁵ Yet uncontrolled bleeding usually requires further blood transfusions with their comparable (but small) risk of transmission of disease. When all else fails to prevent a blood ooze developing into an exsanguinating haemorrhage fibrin glue may save the patient.

H I Atrah 

1. Matras H. Fibrin sea: the state of the art. J Oral Maxillofac Surg 1985;13:605-11.
2. Gibble JW, Ness PM. Fibrin glue: the perfect operative sealant? Transfusion 1990;30:741-7.
3. Kram HB, Nathan RC, Mackabee JR, Klien SR, Shoemaker WC. Clinical use of nonautologous fibrin glue. Am Surg 1988;54:570-3. [Medline]
4. Spotniz WD, Dalton MS, Baker JW, Nolan SP. Reduction of perioperative hemorrhage by anterior mediastinal spray application of fibrin glue during cardiac operations. Ann Thorac Surg 1987;44:529-31. [Abstract]
5. McCarthy PM. Fibrin glue in cardiothoracic surgery. Transfusion Medicine Reviews 1993;7:173-9. [Medline]
6. Ochsner MG, Maniscalco-Theberge ME, Champion HR. Fibrin glue as a hemostatic agent in hepatic and splenic trauma. J Trauma 1990;30:884-7. [Medline]
7. Kennedy JG, Saunders RL. Use of cryoprecipitate coagulum to control tumor -bed bleeding. J Neurosurg 1984;60:1099-101. [Medline]
8. Lagoutte FM, Gauther L, Comte PRM. A fibrin sealant for perforated and preperforated corneal ulcers. Br J Ophthalmol 1989;73:757-61. [Abstract/Free Full Text]
9. Silberstein LE, Williams LJ, Hughlett MA, Magee DA, Weisman RA. An autologous fibrinogen based adhesive for use in otologic surgery. Transfusion 1988;28:319-21. [Medline]
10. Feichtinger V, Barad D, Feinman M, Barg P. The use of two component fibrin sealant for embryo transfer. Fertil Steril 1990;54:733-4. [Medline]
11. Sugiura K, Nakatsuchi Y, Sugimoto Y. A new method for venous interposition grafts using fibrin glue. Microsurgery 1985;6:125-8. [Medline]
12. Baudo F, deCataldo F, Landonio G, Muti G. Management of oral20bleeding in haemophilic patients. Lancet 1988;ii:1082.
13. Thetter O. Fibrin adhesive and its application in thoracic surgery. Thorac Cardiovasc Surg 1981;29:290-2. [Medline]
14. McCarthy PM, Trastek VF, Schaf HV. Esophagogastric anastomoses: the value of fibrin glue in preventing leakage. J Thorac Cardiovasc Surg 1987;93:234-9. [Abstract]
15. Schlag G, Redl H. Fibrin sealant in orthopedic surgery. Clin Orthop 1988;227:269-85. [Medline]
16. Lilius P. Fibrin adhesive: its use in selected skin grafting. Practical note. Scand J Plast Reconstr Surg Hand Surg 1987;21:245-8. [Medline]
17. Kram HB, Bansal M, Timberlake O, Shoemaker WC. Antibacterial effects of fibrin glueantibiotics20mixtures. J Surg Res 1991;50:175-8. [Medline]
18. de Virgilio C, Dubrow T, Sheppard BB. Fibrin glue inhibits intra- abdominal adhesion formation. Arch Surg 1990;125:1378-81. [Abstract]
19. Lindenberg S, Lauriston JG. Prevention of peritoneal adhesion formation by fibrin sealant. Ann Chir Gynaecol 1984;73:11-3. [Medline]
20. Stricker RB, Lane PK, Leffert JD, Rodgers GM, Shuman MA, Corash L. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988;72:1375-80. [Abstract/Free Full Text]
21. Lefrere J-J, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/ detergent-treated anti-haemophilia concentrates. Lancet 1994;343:211-2. [Medline]
22. Evenson SA, Rollag H. Sovent/detergent-treated clotting factors and hepatitis A virus seroconversion. Lancet 1993;341:971-2.
23. Burnouf-Radosevich M, Burnof T, Huart JJ. Biochemical and physical properties of a solvent-detergent-treated fibrin glue. Vox Sang 1990;58:77-84. [Medline]